https://scholars.lib.ntu.edu.tw/handle/123456789/582008
標題: | Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype | 作者: | Huang C.-F. Yu M.-L. JIA-HORNG KAO TAI-CHUNG TSENG Yeh M.-L. Huang J.-F. Dai C.-Y. Lin Z.-Y. Chen S.-C. Wang L.-Y. Juo S.H.H. Chuang W.-L. CHEN-HUA LIU |
公開日期: | 2013 | 卷: | 56 | 期: | 4 | 起(迄)頁: | 293-298 | 來源出版物: | Journal of Clinical Virology | 摘要: | Background: Viral kinetics and host interleukin 28B (IL-28B) genotype determine treatment outcome in hepatitis C virus genotype 1 (HCV-1) infection. Objectives: We aimed to explore the interplay between interferon responsiveness at treatment week 4 and IL28B genotype in the achievement of a sustained virological response (SVR; undetectable HCV RNA 24-weeks after end-of-treatment). Study designs: Rs8099917 genotypes were determined in 528 HCV-1 patients with peginterferon/ribavirin. Interferon responsiveness were evaluated by the degree of week 4 viral reduction: <1 log10 IU/mL, 1-2 logs10 IU/mL, 2-3 logs10 IU/mL, 3-4 logs10 IU/mL and ?4 logs10 IU/mL reduction and/or undetectable HCV RNA, respectively. Results: The SVR rate was significantly higher in patients with great interferon responsiveness at week 4. A great interferon responsiveness was associated with younger age (P<0.0001), lower body mass index (P=0.0056), lower aspartate aminotransferase levels (P=0.0009), higher hemogloblin concentration (P=0.0033), higher platelet counts (P<0.0001), male gender (P<0.0001) and rs809997 TT-genotype (P<0.0001). Comparing to non-TT genotype patients, TT genotype patients had a significantly higher SVR rate with moderate viral reduction (1-3 logs10 IU/mL) at week 4 (58.9% vs. 18.2%, P<0.001), and the SVR rate did not differ between TT/non-TT patients on the extreme ends (<1 or >3 log10 IU/mL reduction) of week 4 interferon responsiveness. For non-TT genotype carriers who were with <3 logs10 reduction, none (0/15) could have a complete early virological response and only 10.9% (7/64) of the patients had an SVR. Conclusions: More profound interferon responsiveness is mandatory for HCV-1 patients with unfavorable IL-28B genotype. ? 2012 Elsevier B.V. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84875094086&doi=10.1016%2fj.jcv.2012.11.015&partnerID=40&md5=3ee3388421cc8a7c37d9830f269828ba https://scholars.lib.ntu.edu.tw/handle/123456789/582008 |
ISSN: | 1386-6532 | DOI: | 10.1016/j.jcv.2012.11.015 | SDG/關鍵字: | aspartate aminotransferase; hemoglobin; interleukin 28B; peginterferon alpha2a plus ribavirin; peginterferon alpha2b plus ribavirin; adult; article; Asian; body mass; clinical feature; female; gene; genetic polymorphism; groups by age; hepatitis C; human; interleukin 28B gene; major clinical study; male; priority journal; RNA virus; sex difference; thrombocyte count; treatment duration; treatment outcome; treatment response; Adult; Age Factors; Aged; Antiviral Agents; Aspartate Aminotransferases; Body Mass Index; Drug Therapy, Combination; Female; Genetic Testing; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Heterozygote; Humans; Interferon-alpha; Interleukins; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Time Factors; Treatment Outcome |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。